Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute.
Autor: | Chute JP; Navy Medical Oncology Branch, National Naval Medical Center and Uniformed Services University of Health Sciences, Bethesda, Maryland 20889-5105, USA., Venzon DJ, Hankins L, Okunieff P, Frame JN, Ihde DC, Johnson BE |
---|---|
Jazyk: | angličtina |
Zdroj: | Mayo Clinic proceedings [Mayo Clin Proc] 1997 Oct; Vol. 72 (10), pp. 901-12. |
DOI: | 10.1016/S0025-6196(11)63359-4 |
Abstrakt: | Objective: To determine the outcome of all patients with small-cell lung cancer (SCLC) treated at the US National Cancer Institute between April 1973 and April 1993. Design: We retrospectively analyzed a series of 594 consecutive patients with SCLC treated at a single institution during a 20-year period to assess changes in duration of survival and toxicity related to various treatment regimens. Material and Methods: For analysis, patients were grouped by decade, and the duration of survival of patients with limited- and extensive-stage SCLC was examined to assess whether patients treated during the first decade of the study (1973 through 1983), when cyclophosphamide-based regimens were used, had different outcomes than those treated during the second decade (1983 through 1993), when cisplatin-based regimens were used. Patients had a minimal follow-up of 2 years. Results: No significant difference was found in the survival of patients with limited- or extensive-stage SCLC treated during the second decade in comparison with during the first decade of the study. Among patients with extensive-stage SCLC, performance status 3 or 4 and metastatic lesions of the liver and central nervous system had a significant adverse effect on survival in both the first and the second decade. Among patients with limited-stage disease, performance status 3 or 4 had the most significant adverse influence on survival during the overall study period. In addition, in a multivariate analysis, etoposide-cisplatin plus twice-daily chest radiotherapy was significantly associated with prolonged survival (P = 0.003). Conclusion: We noted no significant change in the duration of survival of patients with either limited-or extensive-stage SCLC treated at our institution during a 20-year period. A multivariate analysis showed that patients with limited-stage SCLC given a cisplatin-based regimen plus chest radiotherapy lived modestly longer than similar patients given cyclophosphamide regimens at our institution. No evidence was found of changes in pretreatment factors that would affect survival. |
Databáze: | MEDLINE |
Externí odkaz: |